Feb. 14 Quick Takes: Collegium adds analgesic via BioDelivery buyout
Plus Roivant starts new subsidiary and updates from CStone, Astellas and Seagen
Collegium Pharmaceutical Inc. (NASDAQ:COLL) gained a portfolio of marketed products including the opioid analgesic Belbuca buprenorphine buccal film through Monday’s takeout of BioDelivery Sciences International Inc. (NASDAQ:BDSI) for $5.60 per share, or about $604 million on a fully diluted basis. The price represents a 54% premium over BDSI’s Friday close of $3.64. The deal also gives Collegium Elyxyb celecoxib oral solution, which BDSI is in the process of launching to treat acute migraine. BDSI said last month it anticipated $165-$167 million in 2021 sales, mostly from Belbuca.
Weeks after in-licensing an SF3B1 modulator from Eisai Co. Ltd. (Tokyo:4523), Roivant Sciences Ltd. (NASDAQ:ROIV) has set up new unit Hemavant to develop the oral therapy for transfusion-dependent anemia in patients with lower-risk myelodysplastic syndrome. Roivant said the potential first-in-class molecule, RVT-2001, has led to transfusion independence in more than 30% of 19 evaluable patients in a Phase I/II trial, which will be expanded this half...